ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Simon Barry J.

Selecky Christobel

Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter regarding misleading efficacy claims made by executive chairman Dr. Patrick Soon-Shiong about the company's drug Anktiva. The FDA determined that promotional materials falsely suggested Anktiva could treat all cancers, when it is only approved for non-muscle invasive bladder cancer. The announcement caused IBRX shares to plunge over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization. Hagens Berman is investigating claims that ImmunityBio intentionally misled investors.

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) alleging that company defendants made materially false and misleading statements regarding Anktiva's capabilities and the company's business prospects. The lawsuit covers investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026. The lead plaintiff deadline is May 26, 2026.

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

ImmunityBio's stock rose 8.12% in premarket trading after the FDA accepted its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The FDA assigned a PDUFA target action date of January 6, 2027. The Phase 2/3 QUILT 3.032 trial demonstrated strong efficacy with a 12-month disease-free survival rate of 58.2% and 96.0% disease-specific survival at 36 months.

ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug

ImmunityBio presented comparative analyses showing its ANKTIVA plus BCG combination achieved higher complete response rates (69.7%) against nadofaragene firadenovec-vncg (53.4%) and longer response duration (22.1 vs 9.7 months). Against TAR-200, ANKTIVA showed comparable efficacy with significantly fewer adverse events (61.7% vs 83.5%), representing a 68% reduction in treatment-related side effects for BCG-unresponsive bladder cancer patients.

ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) in the U.S. District Court for the Central District of California. The lawsuit alleges that defendants made false and misleading statements regarding Anktiva's capabilities and the company's business operations during the Class Period (January 19, 2026 - March 24, 2026). Investors who purchased ImmunityBio securities during this period and suffered losses have until May 26, 2026, to apply to be appointed as lead plaintiff.

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

Options trader.  My tweets are not investment advice.

DYOptions

Trading & Investing Education 
Inventor : Ripster Cloud System  
Founder: Tenet Trade Group
https://t.co/0qpaN2fM0W
 https://t.co/GP2vE0fon3

Ripster

Son of Market Gods ▪️equity market handicapper/speculator since '97 ▪️sweepers + sentiment = edge, check out a 7-day trial ?? https://t.co/YSzVEQH8EA

WALL ST JESUS

Former scientist at a major biotech for 15+ yrs, now I trade stocks daily. Tweets are for entertainment only - not investment advice.

Immunitybio Inc (IBRX) Stock Price, Analysis & Trade Signals